Astrana Health (ASTH) has been in focus after Q1 earnings, where management highlighted strong revenue growth, increasing use of full risk contracts, and progress integrating the Prospect acquisition alongside its AI driven care platform.

Astrana Health's share price sits at $37.38 after a recent 1 day decline of 3.56% and 7 day fall of 4.55%. However, the 30 day share price return of 14.84% and 90 day gain of 88.22% highlight strong recent momentum, with the 1 year total shareholder return of 52.76% and 3 year total shareholder return of 20.19% putting the shorter term move into a longer performance context.

If Q1 results and new physician partnerships have caught your attention, it can be useful to see what else is emerging in healthcare technology and AI, starting with 33 healthcare AI stocks

With Astrana trading at $37.38 alongside a reported intrinsic discount of about 69%, a value score of 2, and a price target above the current level, the key question is whether there is still a buying opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 4% Overvalued

The most followed narrative puts Astrana Health's fair value at $36, slightly below the last close of $37.38. This frames the recent rally as relatively full against that estimate.

Long-term tailwinds from regulatory and payer shifts towards alternative payment models and value-based healthcare are expanding the addressable market and favor operators with mature, risk-bearing platforms like Astrana. This is described as setting the stage for durable revenue and profit growth as national healthcare expenditure rises.

Curious what financial engine sits behind that valuation call? The narrative leans heavily on expectations for rapid earnings expansion, firmer margins, and a slimmer future earnings multiple. The mix may surprise you.

Result: Fair Value of $36 (OVERVALUED)

However, there are still clear pressure points, including heavy exposure to government reimbursement decisions and the risk that Prospect integration or AI rollouts could add cost without delivering the expected benefits.

Another Way to Look at Value

The analyst narrative pegs Astrana Health's fair value at $36, slightly below the current $37.38. Our DCF model points in a very different direction, with a future cash flow value estimate of $120.25 that implies the stock trades about 69% below that mark. Which set of assumptions do you trust more for the long haul?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Astrana Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 53 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With such a split view on value and momentum, it helps to look past the headlines and quickly weigh the full risk reward picture for yourself using 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Astrana has sharpened your focus, do not stop here. Use the screener to quickly spot other stocks where quality, value, and resilience line up.

• Target strong fundamentals and steady balance sheets by scanning solid balance sheet and fundamentals stocks screener (46 results) that can help anchor your portfolio.
• Hunt for potential mispricing by reviewing 53 high quality undervalued stocks that combine quality metrics with room for a more optimistic market view.
• Dial back risk while staying invested by checking 66 resilient stocks with low risk scores that aim to offer stability when volatility picks up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.